These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36502999)

  • 1. Atrial fibrillation: Epigenetic aspects and role of sodium-glucose cotransporter 2 inhibitors.
    Donniacuo M; De Angelis A; Telesca M; Bellocchio G; Riemma MA; Paolisso P; Scisciola L; Cianflone E; Torella D; Castaldo G; Capuano A; Urbanek K; Berrino L; Rossi F; Cappetta D
    Pharmacol Res; 2023 Feb; 188():106591. PubMed ID: 36502999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in atrial fibrillation: A reappraisal.
    Doñate Puertas R; Arora R; Rome S; Asatryan B; Roderick HL; Chevalier P
    Heart Rhythm; 2021 May; 18(5):824-832. PubMed ID: 33440248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological approaches in the treatment of atrial fibrillation.
    Tamargo J; Caballero R; Delpón E
    Curr Med Chem; 2004 Jan; 11(1):13-28. PubMed ID: 14754423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sodium-Glucose Cotransporter 2 Inhibitors Potentially Prevent Atrial Fibrillation by Ameliorating Ion Handling and Mitochondrial Dysfunction.
    Peng X; Li L; Zhang M; Zhao Q; Wu K; Bai R; Ruan Y; Liu N
    Front Physiol; 2020; 11():912. PubMed ID: 32848857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review.
    Ouyang X; Wang J; Chen Q; Peng L; Li S; Tang X
    Cardiovasc Diabetol; 2023 May; 22(1):124. PubMed ID: 37226247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of interleukins in pathogenesis and prognosis of atrial fibrillation.
    Lotfi ME; Pezeshki PS; Rezaei N
    Expert Rev Clin Immunol; 2023 Jun; 19(6):585-597. PubMed ID: 36964672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus.
    Fauchier L; Boriani G; de Groot JR; Kreutz R; Rossing P; Camm AJ
    Europace; 2021 Dec; 23(12):1873-1891. PubMed ID: 34411235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin: A sodium-glucose cotransporter 2 inhibitor, attenuates angiotensin II-induced atrial fibrillation by regulating atrial electrical and structural remodeling.
    Zhan G; Wang X; Wang X; Li J; Tang Y; Bi H; Yang X; Xia Y
    Eur J Pharmacol; 2024 Jun; 978():176712. PubMed ID: 38906237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy of sodium-glucose cotransporter 2 inhibitor therapy in preventing atrial fibrillation recurrence after catheter ablation in type 2 diabetes mellitus patients.
    Liu HT; Wo HT; Chang PC; Lee HL; Wen MS; Chou CC
    Heliyon; 2023 Jun; 9(6):e16835. PubMed ID: 37332966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Metab; 2022 Nov; 48(6):101390. PubMed ID: 36170946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial fibrillation: mechanisms, therapeutics, and future directions.
    Pellman J; Sheikh F
    Compr Physiol; 2015 Apr; 5(2):649-65. PubMed ID: 25880508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Na+-channel blockade on the three-dimensional substrate of atrial fibrillation in a model of endo-epicardial dissociation and transmural conduction.
    Gharaviri A; Verheule S; Eckstein J; Potse M; Krause R; Auricchio A; Kuijpers NHL; Schotten U
    Europace; 2018 Nov; 20(suppl_3):iii69-iii76. PubMed ID: 30476060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel approaches for pharmacological management of atrial fibrillation.
    Ehrlich JR; Nattel S
    Drugs; 2009; 69(7):757-74. PubMed ID: 19441867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions.
    Shetty SS; Krumerman A
    Cardiovasc Diabetol; 2022 Jun; 21(1):119. PubMed ID: 35764968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
    Nishinarita R; Niwano S; Niwano H; Nakamura H; Saito D; Sato T; Matsuura G; Arakawa Y; Kobayashi S; Shirakawa Y; Horiguchi A; Ishizue N; Igarashi T; Yoshizawa T; Oikawa J; Hara Y; Katsumura T; Kishihara J; Satoh A; Fukaya H; Sakagami H; Ako J
    J Am Heart Assoc; 2021 Jan; 10(2):e017483. PubMed ID: 33399004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of atrial Ca(2+) handling as cause and consequence of atrial fibrillation.
    Greiser M; Lederer WJ; Schotten U
    Cardiovasc Res; 2011 Mar; 89(4):722-33. PubMed ID: 21159669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.